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Impact of biobanks on research outcomes
in rare diseases: a systematic review
Monique Garcia1, Jenny Downs2,3, Alyce Russell1 and Wei Wang1,4,5*
Abstract
Background: Alleviating the burden of rare diseases requires research into new diagnostic and therapeutic
strategies. We undertook a systematic review to identify and compare the impact of stand-alone registries, registries
with biobanks, and rare disease biobanks on research outcomes in rare diseases.
Methods: A systematic review and meta-aggregation was conducted using the preferred reporting items for
systematic reviews and meta-analyses (the PRISMA statement). English language publications were sourced from
PubMed, Medline, Scopus, and Web of Science. Original research papers that reported clinical, epidemiological,
basic or translational research findings derived from data contained in stand-alone registries, registries with
biobanks, and rare disease biobanks were considered. Articles selected for inclusion were assessed using the critical
appraisal instruments by JBI-QARI. Each article was read in its entirety and findings were extracted using the online
data extraction software from JBI-QARI.
Results: Thirty studies including 28 rare disease resources were included in the review. Of those, 14 registries were
not associated to biobank infrastructure, 9 registries were associated with biobank infrastructure, and 6 were rare
disease biobank resources. Stand-alone registries had the capacity to uncover the natural history of disease and
contributed to evidence-based practice. When annexed to biobank infrastructure, registries could also identify and
validate biomarkers, uncover novel genes, elucidate pathogenesis at the Omics level, and develop new therapeutic
strategies. Rare disease biobanks in this review had similar capacity for biological investigations, but in addition, had
far greater sample numbers and higher quality laboratory techniques for quality assurance processes.
Discussion: We examined the research outcomes of three specific populations: stand-alone registries, registries
with biobanks, and stand-alone rare disease biobanks and demonstrated that there are key differences among
these resources. These differences are a function of the resources’ design, aims, and objectives, with each resource
having a distinctive and important role in contributing to the body of knowledge for rare disease research. Whilst
stand-alone registries had the capacity to uncover the natural history of disease, develop best practice, replace
clinical trials, and improve patient outcomes, they were limited in their capacity to conduct basic research. The role
of basic research in rare disease research is vital; scientists must first understand the pathways of disease before
they can develop appropriate interventions. Rare disease biobanks, on the other hand (particularly larger biobanks),
had the key infrastructure required to conduct basic research, making novel Omics discoveries, identify and validate
biomarkers, uncover novel genes, and develop new therapeutic strategies. However, these stand-alone rare disease
biobanks did not collect comprehensive data or impact on clinical observations like a rare disease registry.
Rare disease research is important not only for rare diseases, but also for also common diseases. For example,
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research of low-density lipoprotein (LDL)-receptors in the rare disease known as familial hypercholesterolemia led to
the discovery of statins, a drug therapy that is now used routinely to prevent heart disease.
Conclusions: Rare diseases are still under-researched worldwide. This review made the important observation that
registries with biobanks had the function of both stand-alone registries (the capacity to collect comprehensive
clinical and epidemiological data) and stand-alone rare disease biobanks (the ability to contribute to Omics
research). We found registries with biobanks offer a unique, practical, cost-effective, and impactful solution for rare
disease research. Linkage of stand-alone registries to rare disease biobanks will provide the appropriate resources
required for the effective translation of basic research into clinical practice. Furthermore, facilitators such as
collaboration, engagement, blended recruitment, pro-active marketing, broad consent, and “virtual biobank” online
catalogues will, if utilised, add to the success of these resources. These important observations can serve to direct
future rare diseases research efforts, ultimately improve patient outcomes and alleviate the significant burden
associated with rare disease for clinicians, hospitals, society, and most importantly, the patients and their families.
Keywords: Rare disease, Registries, Biobank, Systematic review
Background
Rare diseases (RDs), also known as “orphan” or “neglected”
diseases, occur in small proportions of the population. The
European Union (EU) consumer-endorsed definition of
RDs is those with “life-threatening or chronically debilitat-
ing diseases which are of such low prevalence (1 in 2,000
people) that special combined efforts are needed to ad-
dress them” [1]. Most RDs occur during childhood and are
often disabling, incurable, painful, and cause great suffer-
ing [2]. In Western Australia (WA), a recent data linkage
study found 467 RDs were logged in hospital records with
a discharge date between 1 July 1999 and 31 December
2010, accounting for 2% of the WA population [3]. The
study also showed approximately 10% of all hospital ad-
missions in WA were related to RDs. Moreover, RDs
accounted for 10.5% of total WA hospital expenditure
($395 million) over 1 year [3]. Very few RDs have effective
treatments [4], and therefore, RDs continue to place a sig-
nificant burden on the healthcare system [5].
New diagnostic and therapeutic strategies are urgently
needed to manage RDs, with registries being recognised as
an effective tool to advance RD research [5]. National and
international registries for RDs are necessary to bring to-
gether patients to facilitate research, as patient numbers in
local jurisdictions for each RD are too few [5]. Orphanet,
an online catalogue of over 6000 RDs and directory of ex-
pert resources for participating countries, recently stated
that RD registries are “the only way to pool data in order
to achieve a sufficient sample size for epidemiological and/
or clinical research” [6]. For example, the Australian Rett
Syndrome Database, established in 1993 to investigate this
rare neurodevelopmental disorder, has led to a greater un-
derstanding of the natural history of disease, impact of
treatment, and facilitated more than 100 research publica-
tions on Rett syndrome [7]. As well as clinical data, some
RD registries also collect biological samples, such as blood.
These samples are processed and stored in specialised
freezers as a biobank (BB). BBs, also referred to as “bio-
logical specimen banks”, “tissue banks” or “biorepositories”,
link a patient’s biological sample to their clinical data, pro-
viding detailed phenotypic and genotypic information. The
aim of a BB is to then make samples and data available to
the scientific community for further studies. The United
Kingdom BB is one of the world’s largest, with over
500,000 participants aged between 40 and 69 years [8]. The
open-access resource enables investigations of genetic and
environmental causes of diseases to improve the preven-
tion, diagnosis, and treatment of diseases affecting the
greater community [9]. Whilst BBs require significant com-
mitment, planning and long-term funding, the benefits of
drug discovery far outweigh these costs [13]. This is espe-
cially so with RDs, where “every sample counts” [14].
RDs have been referred to as “fundamental diseases”,
providing opportunities to investigate the “extremes of
human pathology” whilst also affording unique insights
into normal and abnormal human physiology [10, 11].
This leads to a greater understanding of biological path-
ways and the identification of therapeutic strategies not
only for RDs, but also common diseases [12]. For ex-
ample, research of low-density lipoprotein (LDL)-recep-
tors in familial hypercholesterolemia, a RD, led to the
discovery of statins, a drug therapy that is now used rou-
tinely to prevent heart disease [11]. We undertook a sys-
tematic review to identify the impact of BBs and
interventions derived from BB infrastructure on research
outcomes in RDs, and compared research outcomes
from stand-alone registries (REG), registries with BBs
(REG + BB), and stand-alone Rare Disease Biobanks
(RDBB) We also aimed to provide recommendations for
practice and policy.
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Methods
Research design
A systematic review and meta-aggregation was conducted
using the preferred reporting items for systematic reviews
and meta-analyses (the PRISMA statement) [15]. The
Joanna Briggs Institute Qualitative Assessment and Re-
view Instrument (JBI-QARI) method of meta-aggregation
was used for critical appraisal of articles, data extraction,
and synthesis of data [16]. This qualitative method was de-
veloped to mirror the Cochrane’s collaboration processes
for quantitative systematic reviews.
Search strategy
All articles from 1991 to 2016, to include the
pre-genomic and genomic era, and published in English
were considered. PubMed, Medline, Scopus and Web of
Science databases were utilised. The following search
terms were used: Rare diseases OR neglected diseases
OR orphan diseases AND Biological Specimen Bank OR
tissue bank OR registries/standards* OR registries/ther-
apies* OR biobank* OR biorepository.
Eligibility criteria
Original research papers that reported clinical, epidemio-
logical, basic or translational research findings derived
from data contained in a REG, REG + BB, or RDBB were
included. For the purpose of this study, a registry was de-
fined as any database that collected any of the following
types of data sets: basic, epidemiological, clinical and com-
prehensive data. All study designs were included. Re-
trieved articles were initially screened by title and abstract,
and if potentially eligible, their full-text was reviewed.
Critical appraisal
Articles selected for inclusion were assessed using the
critical appraisal instruments by JBI-QARI. Two re-
searchers performed the critical appraisal and compared
results. In the instance of disagreement, a third party
was sought, and consensus was reached.
Data extraction
Four domains were developed for the data coding
sheet – study quality, methodology, type of interven-
tion, and data/specimen collection fields. Each article
was read in its entirety and findings were extracted
using the online data extraction software from
JBI-QARI. Findings were recorded as verbatim quotes
of the original articles author’s interpretation of re-
sults. An illustration (direct quote) was included to
support each finding. Findings were assigned a level
of plausibility (unequivocal or credible).
Data synthesis
Data was synthesised using meta-aggregation analysis
[16]. The findings were grouped through similarity of
meaning. Categories were developed to describe the con-
cepts within each group of findings, with at least two
findings per category. The categories were then grouped
into a synthesised finding with at least two categories
per synthesis. Categories were further grouped into six
themes: basic science, translational science, clinical ob-
servation, clinical treatment, study quality, and facilita-
tors and barriers. The synthesised findings constituted
the set of recommendations for practice and policy.
Results
The initial search retrieved 433 citations. Articles were
then screened by title and abstract. Only articles whose
abstracts reported results directly pertaining to the pri-
mary aims, objectives, and outcomes of the resource it-
self were included. Articles that reported findings of a
study that came about as a consequence of the resource
were excluded. As a result, 311 citations were excluded.
The remaining 122 articles were retrieved with their full
text reviewed. Only articles that reported the following
were included: type of resource established, methodology
(such as data collection, consent process, recruitment,
number of participants, and funding), and primary out-
comes of the resource including clinical, epidemiological,
basic or translational research findings. Of those, 92 did
not meet the eligibility criteria, with a total of 29 articles
included in the review Fig. 1.
The 29 studies included 28 RD resources. There were
nine REG + BB, 14 REG, and six RDBB. Of the nine
REG + BB, six were international networks, and three
were national networks. Of the 14 REG, nine were inter-
national networks, and five were national networks. Of
the six RDBB, two were international networks, three
were national networks, and one was a single site initia-
tive. The registries were European (n = 12), International
(n = 7), North American (n = 4), Australian and New
Zealand (n = 3), Japanese (n = 1), and Canadian (n = 1).
Twenty-one registries were established since 2000, with
eight established since 2010. Studies were mainly pro-
spective and longitudinal in design, with only a few regis-
tries collecting retrospective or cross-sectional data.
Disease categories included cancer, genetic, neuromuscu-
lar, neurological, lung diseases, cardiovascular, urogenital/
renal, autoimmune, autoinflammatory, endocrine, blood,
and hereditary ocular diseases.
Study quality
Registry cohorts ranged from paediatrics to adults or in-
cluded both children and adults. REG, REG + BB, and
RDBB cohort sizes ranged from 23 to greater than 13,500
participants. The total number of biospecimens collected
Garcia et al. Orphanet Journal of Rare Diseases          (2018) 13:202 Page 3 of 13
ranged from 46 to over 500,000. The number of research
projects emanating from REG, REG + BB, and RDBB
ranged from 1 to 784, with the number of research publi-
cations ranging from 1 to 255 since the project started.
Twenty registries listed their funding sources: four were
funded by the European Commission; three were funded
by pharmaceutical companies; two by each of the follow-
ing including the Department of Health, foundations, in-
stitutes, and research trusts; one from either university,
charity, society, or benefactor funds; and one from a var-
iety of sources. Four registries reported funding amounts
($170,000 per annum, 1.22 Million, 1.6Million and unre-
stricted funding). Nineteen registries reported that their
data and samples are available to researchers. All registries
specified the RD name of interest, yet only five used the
World Health Organisation (WHO), International Classi-
fication of Disease (ICD) or the Online Mendelian Inherit-
ance in Man (OMIM) coding systems. A list of the
registries, and their association with BBs at the time the
original article was published, can be found in Table 1.
Themes
The synthesis generated 492 findings, 34 categories, and
six themes. The themes were titled basic science, trans-
lational science, clinical observation, clinical treatment,
study quality, and facilitators and barriers. Synthesised
Themes and Categories identified in REG, REG + BB,
and RDBB can be found in Table 2.
Basic science
Omics Both REG + BB and RDBB impacted on RD re-
search outcomes by facilitating Omics studies and
discoveries. No evidence of basic science research being
conducted in REG was found. The basic science discover-
ies included the characterisation of new syndromes, bio-
marker discovery and validation, elucidation of biological
pathways involved in disease, molecular modelling of
pathogenic variants, characterisation of epigenetic factors
involved in disease expression, genotype-phenotype corre-
lations, molecular analysis of DNA methylation, chroma-
tin structure, gene-transfection and gene-silencing studies,
studies involving growth factors and cytokines, identifica-
tion of new gene and novel mutations, and exon-skipping
[17–19].
Epidemiology and studies of phenotype REG, REG +
BB, and RDBBs all impacted on RD research outcomes
with regards to epidemiological studies including the in-
cidence/prevalence of the disorder and survival, natural
history, relationships between genotype and phenotype,
and understanding the burden of disease. Captured epi-
demiological data in this review included age, character-
isation of symptoms, gender distribution, ethnic
background, provision of care at different sites, diagnosis
of patient, and data pertaining specifically to the disease
of interest [20–25].
Translational science
Availability of biospecimens for research This review
found that both REG + BB and RDBBs impacted on
RD research outcomes in translational science by con-
tributing biological specimens to research projects,
leading to new therapies to treat RD. REG could not
contribute biological specimens, and so lacked the
Fig. 1 Flow diagram for article section and inclusion of review. The search retrieved 432 citations; 311 were excluded, with full text retrieved for
109. Of those, 79 did not meet the eligibility criteria. A total of 30 articles were included in the review
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Table 1 List of RD resources
Study ID Author Link to resource
(reference number)
Resource name Registry with
Biobank
(REG + BB)
Stand-alone
registry onlya
(REG)
Stand-alone Rare
DiseaseBiobank
(RDBB)
Themes
associated
with resource
N1–001 O’Souji, C [31] The Children’s Oncology Rare
and Cutaneous NHL registry
2 CO, CT, B
N1–002 Mora, M [17] The Eurobiobank Network 2 BS, T, CT, F, B
N1–003 Filocomo, M [19] Telethon Network of Genetic
Biobanks
2 BS, T, CO, F, B
N1–004 Ebner, K [27] The European ARPKD registry 2 CO, CT, F
N1–005 Blain, D [18] Eyegene 2 BS, CT, F
N1–006 Bush, A [32] European Management Platform for
Childhood Interstitial Lung Diseases
2 CT, F
N1–007 Martin, N [29] The UK JDM cohort biomarker study and
repository Juvenile Dermatomyositis
(UK and Ireland) Cohort Biomarker
study and Repository for Idiopathic
Inflammatory Myopathies
2 CO, CT, F, B
N1–008 Fisher, C [25] The PTS registry and biobank
network - an AOSpine Knowledge
forum tumour study
2 BS, CO, CT, F, B
N1–009 Ugolini, D [35] The CREST biorepository 1 F
N1–010 Brandenburg,
V
[24] The German Calciphylaxis registry 1 BS, CO, CT, F, B
N1–011 Struik, M [48] The Dutch Lymphangioleiomyomatosis
(LAM) registry
1 F
N1–012 Squitieri, F [49] Italian Huntington Disease
patients - data and tissue bank
1 F
N1–013 Li, J [13] Friedrich’s Ataxia fibroblast repository 1 F
N1–014 Zhou, L [14] The Tumour Bank at the Children’s
Hospital Westmead (TB-CHW)
0 F
N1–015 Bladen, C [33] The TREAT-NMD Duchenne
Muscular Dystrophy Registries
2a CT, B
N1–016 Webb, S [30] The European Registry of Cushing’s
Syndrome (ERCUSYN) registry
2 CO, CT, F
N1–017 Sharkey, E [47] The NF1 Patient Registry Initiative 2 CO
N1–018 Rodger, S [23] The TREAT-NMD care and trial
site registry
2 BS, CO, F, B
N1–019 Tilson, H [26] The Cryopyrin-associated periodic
syndrome (CAPS) registry
2 T, CO, CT, F, B
N1–020 Mistry, P [28] The International Collaborative Gaucher
Group (ICGG) Gaucher registry
2 CO, CT
N1–021 Evangelista, T [21] The UK Facioscapulohumeral
muscular dystrophy patient registry
1a BS, CO, CT, F, B
N1–022 Hilbert, J [22] The National Registry of
Myotonic Dystrophy (MD) and
Facioscapulohumeral (FSHD)
1 BS, CO, F
N1–023 Fasnacht, M [20] The Swiss Registry for Pulmonary
Arterial Hypertension
1 BS, CO, CT, F
N1–024 Downs, J
Leonard H,
Louise, S
[7, 51] The Australian Rett Syndrome
Database
The InterRett Database
1
2
CO, F
N1–025 Korngut, L [34] The Canadian Neuromuscular
Disease Registry (CNDR)
1 F, B
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capacity to contribute to the development of new
diagnostic tools and therapies. Both REG + BB and
RDBB in this review donated biological samples to
pharmaceutical companies (e.g.Pfizer), consortiums,
and international studies [19].
Clinical trials This review found that REG, REG + BB,
and RDBB all impacted on RD research outcomes in
clinical trials with regards to increased patient recruit-
ment and novel safety monitoring approaches. It was
found that REG may offer the possibility of study designs
Table 1 List of RD resources (Continued)
Study ID Author Link to resource
(reference number)
Resource name Registry with
Biobank
(REG + BB)
Stand-alone
registry onlya
(REG)
Stand-alone Rare
DiseaseBiobank
(RDBB)
Themes
associated
with resource
N1–026 Fehr, S [50] The International CDKL5
Disorder Database
2 CO, F
N1–027 Akbarnia, B The Growing Spine Study Group 2 CO, CT, F
N1–028 Tada, M [52] The Rare Disease Bank of Japan:
establishment, current status and future
challenges
1 F, O
BS Basic Science, T Translational Science, CO Clinical Observation, CT Clinical Treatment, F Facilitators, B Barriers, 0–Single site,
1–National, 2–International
aDenotes registries that, in addition to collecting clinical data, also collect genetic information. These registries do not collect or store biological
samples, and as such, are still considered registries only
Table 2 Synthesised Themes and Categories identified in stand-alone registries, registries linked to Biobanks, and stand-alone Rare
Disease Biobanks
Theme Theme code Category Linked resource (ref.) Identified in registries
linked to Biobanks
(REG + BB)
Identified in
stand-alone
registries (REG)
Identified in stand-alone
Rare Disease Biobanks
(RDBB)
Basic Science BS Omics [14, 52, 17, 18, 29, 35, 48, 19, 13, 31] ✓ ✓
Biomarker
development
[32, 35, 29] ✓
Subcohort
identification
[13, 25, 35, 21, 27] ✓ ✓
Epidemiology [48, 33, 21, 24, 26, 20, 22, 29,
35, 23, 30, 19, 34]
✓ ✓ ✓
Translational
science
T Increased research
projects
[14, 33, 21, 23, 17, 30, 19, 22, 29, 18, 34] ✓ ✓ ✓
Randomised
controlled trials
[48, 33, 34, 32, 22, 23, 21, 27, 29] ✓ ✓
Biospecimen
contribution
to studies
[31, 17, 19, 27, 18, 32, 29, 25, 35,
24, 48, 49, 13, 14]
✓ ✓
Clinical observation CO Diagnosis/
survival rate
[28, 29, 25, 20, 19, 50, 51] ✓ ✓
Natural history
of disease
[31, 24, 27, 30, 23, 21, 28, 22, 29] ✓ ✓
Clinical treatment CT Diagnostics [17, 18, 33] ✓ ✓
Guidelines
for treatment
[32, 20, 21, 33, 25, 29] ✓ ✓
Treatment evaluation [26, 27, 30, 31, 20, 28, 33, 29, 25, 24] ✓ ✓
Facilitators F Benefits to
stakeholders
[23, 17, 18, 14, 32, 19, 22, 13] ✓ ✓ ✓
Collaborations [24, 48, 20, 13, 26, 22, 17, 18, 32,
29, 33, 35, 30, 25, 49, 19, 21, 27]
✓ ✓ ✓
Engagement [29, 30, 32, 34, 35] ✓ ✓ ✓
Recruitment [34] ✓
Pro-active
marketing
[14] ✓
Barriers B Challenges [13, 17, 19, 21, 23–26, 29, 31, 33, 34] ✓ ✓ ✓
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other than randomised controlled trials (RCT), hence
they are often more advantageous [26]. Unlike RCTs,
registries may have access to a large cohort, and have no
dictated treatment regimens or strict inclusion criteria
[26]. REG have the capacity to collect information from
patients in a real world setting during routine clinical care,
and because they are observational, all patients receiving
treatment can be included, irrespective of dosage. This
brings sound external validity as ‘registry enrolled patients’
generally have an increased baseline risk than ‘RCT en-
rolled patients’. Further, the research period of observation
by registries is longer than most RCTs, allowing long-term
follow up of new approved therapies.
Increased research activity There is overwhelming evi-
dence that REG and REG + BB significantly increase the
number of research projects, and this is amplified when
it is a member of a network. Comparatively, RDBBs gen-
erated quantifiably more research activity and publica-
tions than REG and REG + BB. For example, the use of
samples from a European BB network has been acknowl-
edged in 255 publications from 2004 to 2013 [17]. An
Italian network provided thousands of samples to na-
tional and international researchers over a 5-year period
[19]. This led to 784 research projects, with over 250 sci-
entific publications from 2008 to 2012 [19]. In this re-
view, research projects and enquiries totalled 886 for
RDBB, 172 for REG, and 12 for REG + BB. Further, re-
search publications totalled 571 for RDBB, 26 for REG,
and 0 for REG + BB. This low number from REG + BB
may be attributed to the fact that the majority of these
resources had only recently been established (Fig. 2).
Clinical observation
Natural history of disease Both REG and REG + BB
gained insights into the natural course of disease. No
RDBB in this review contributed to uncovering the nat-
ural history of disease due to the lack of phenotypic
data. Registries in this review observed factors that ac-
celerated or slowed development of disease, understood
better the resultant disease sequelae, and made new
findings regarding disease progression [20–30].
Diagnosis, survival rates, patient outcomes REG, REG
+ BB, and RDBBs all impacted clinical observation out-
comes in regard to diagnosis, survival rates and patient
outcomes. REG in this review observed long delays be-
tween symptom onset and diagnosis, with multiple con-
sults by specialists observed prior to gaining a confirmed
diagnosis [7, 20, 29, 31]. RDBBs had the capacity to store
samples for clinicians from undiagnosed patients with
the view at future diagnosis, providing retrospective
diagnoses [19]. Further, it was found that REG could es-
tablish survival rates for various RDs, as well as out-
comes at follow-ups in this review [28].
Clinical treatment
Diagnostics This review found that both REG + BB and
RDBBs supported the development of new diagnostic
testing methodologies, whilst REG contributed to ob-
serving which participating centres lacked appropriate
diagnostic criteria. [17, 18, 23]
Guidelines for treatment Both REG and REG + BB im-
pacted on clinical treatment. RDs commonly lack
evidence-based treatment protocols, attributed to the
low number of patients seen at any one centre. REG in
this review facilitated multi-centre collaboration, which
in turn led to discussions among experts regarding treat-
ment protocols and best practice [20, 21, 25, 29, 32, 33].
This contributed to the management of disease, impact-
ing on patient outcomes.
Fig. 2 Research impact of RD resources. In this review, research projects and enquiries totalled 886 for RDBB, 172 for REG, and 12 for REG + BB.
Further, research publications totalled 571 for RDBB, 26 for REG, and 0 for REG + BB
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Treatment evaluation REG and REG + BB impacted on
treatment evaluation for RD. In this review, no RDBB was
directly involved in treatment evaluation studies. Existing
therapies and surgical interventions, and their outcomes,
were observed. This led to a greater understanding of
which therapies affected disease course [20, 24–31, 33].
Facilitators
Benefits to stakeholders REG, REG + BB, and RDBB all
benefit stakeholders. This review found that participants,
patient advocacy groups, researchers, and clinicians all
benefited from participation in RD resources [13, 14,
17–19, 21–23, 32].
Collaborations This review found collaborations between
all three RD resources and various stakeholders are vital
to the success of the registries aims and objectives. All re-
sources collaborated with numerous groups including hos-
pital sites, academic centres, clinicians, patients, scientists,
patient advocacy groups, pharmaceutical and diagnostic
industries, societies, foundations and other registries. Col-
laboration was local, regional, national, or international.
Collaborative approaches facilitated review and discussion
of treatment protocols, improving treatment outcomes
[13, 14, 17–22, 24–27]. Continuous engagement assisted
clinicians with follow-up, with more complete data being
reported. International collaborations increased patient
cohort size, leading to increased interest from industry.
Engagement Engagement strategies reported by all re-
sources included the international nature of the registry,
ongoing communication between the registry and par-
ticipating sites, collaboration, methods of recruitment,
using data collection forms in place of clinical notes to
ease the burden of form filling, inclusion of any inter-
ested clinics to increase participant numbers, and equal
sharing of funding leading to continuation of data collec-
tion even when the funding ceased [29, 30, 32, 34, 35].
Recruitment All resources in this review employed novel
methods for the recruitment of RD patients. This lateral
thinking is especially important given the small number of
patients that are scattered geographically [34].
Pro-active marketing A strategic, targeted, pro-active
marketing approach demonstrated how even a single BB
site can have a significant impact on RD research out-
comes, and can contribute to key research studies
throughout the world [14].
Barriers
Challenges are reported by all three resource types.
Challenges faced by REG included incomplete data sets,
data accuracy (error), lack of follow-up data, lack of
standardisation, and funding restrictions [17, 19, 21, 23–
26, 29, 31, 33, 34]. Another challenge was the ability to
reach, recruit and capture all patient cases. Challenges
faced by REG + BB and RDBBs in this review included
difficulties when implementing next-generation sequen-
cing (NGS) due to legal and ethical concerns [19].
Current informed consent can be restricted to that pa-
tient’s particular disease, lacking the necessary broad con-
sent to implement NGS [19]. Moreover, governing the
sheer volume of information generated by NGS required
additional considerations such as when managing “inciden-
tal findings” [19]. It was also found that BBs which cover a
broad range of diseases are limited in their ability to reach
a critical mass for a particular disease category [13].
The aforementioned challenges are just some of the
barriers faced by resources in the process of sample ac-
quisition and storage. Governance Frameworks need to
be developed by resources to overcome these obstacles.
Such an example is the framework that has been devel-
oped, the Office of Population Health Genomics, the
Western Australia Health Department [53]. The frame-
work, titled “Guidelines for human biobanks, genetic re-
search databases and associated data” provides a
comprehensive manual for registries and biobanks and
considers important constraints arising from the use of
biological specimens [53]. Issues such as establishment
of the resource, governance, ethics, participation (includ-
ing enrolment, consent/assent, and withdrawal pro-
cesses), protection of samples and data (privacy,
confidentiality, security), standard operating procedures,
access of samples (access regulations, return of inciden-
tal findings), and benefit sharing (intellectual property,
income generation, royalties) are discussed [53]. Rare
Disease sample collection, however, is fraught with even
more unique barriers, as considered by Tada et al., who
reports difficulties in bank operation, updating sample
information, and technical improvement [52]. The Tele-
thon Network of Genetic Biobanks documents insightful
solutions in overcoming these challenges, specifically for
RD. [19] Their report details governance, management
and IT framework solutions to achieve standardization
and best practice, whilst also considering sustainability,
regulations and national/international laws [19].
Discussion
This review sought to identify and compare the impact
of REG, REG + BB, and RDBB on research outcomes in
RD. We analysed and compared the research endpoints
of three specific resource populations: REG, REG + BB,
and RDBBs. Findings were grouped into themes: basic
science, translational science, clinical observation, clin-
ical treatment, facilitators, and barriers. We observed
key differences among the research endpoint variables
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between all three RD resources. Most notably, REG + BB
and RDBBs included basic science (Omics) as a research
endpoint, observed to lie exclusively within the domain
of REG + BB and RDBBs. In comparison to REG, the in-
clusion of basic science as a research endpoint variable
in REG + BB and RDBBs was found to have significant
and far-reaching consequences by way of facilitating
translational research, leading to the discovery and de-
velopment of new treatments and therapies for RDs.
Importantly, REG of RD are often the only resource for
the disease of interest [36]. REG are gradually being
recognised as a global priority in RD research; the essen-
tial “building blocks” for RD epidemiological, clinical re-
search and post-marketing studies [37]. We found REG
led to a greater understanding of the natural history of
disease, established consensus-driven treatment proto-
cols, replaced clinical trials, and ultimately improved
patient outcomes. Despite these benefits, REG were re-
stricted in their smaller capacity to contribute to basic
research, attributable to a lack of infrastructure required
to conduct the necessary laboratory-based investigations.
Both REG + BB and RDBBs contributed to basic re-
search. Findings included novel Omics discoveries, bio-
marker development (screening, validation, replication
and clinical trial), gene identification, elucidation of bio-
logical and cellular pathways, models for drug-screening,
and therapeutic discoveries. Further, basic research stud-
ies are made possible through the availability of human
biological specimens [14]. It is only through the collec-
tion and investigation of human biological samples
matched to clinical data, such is the case with REG + BB
and RDBBs, that novel diagnostic, prognostic, and thera-
peutic avenues can be developed [25]. This is particularly
important considering drug innovation for RD has, in re-
cent years, become progressively focused on Omics stud-
ies, with the identification of molecular targets leading to
the development of new therapies [10]. The development
of new therapies for RDs is critically significant as they
can be of a life-saving nature. This is best demonstrated
by Strimvelis, the first ex vivo stem-cell gene-therapy for
children to gain marketing approval anywhere in the
world [38]. In spite of the ground-breaking success of
Strimvelis, Fondazione Telethon remains committed to its
original focus of basic research, stating “basic science is
the foundation on which future treatments will be devel-
oped” [12]. This provides a powerful message to RD stake-
holders; scientists must first understand the pathways of
disease before they can develop appropriate interventions.
The premise that basic science is the key component in
REG+BB and RDBBs for the discovery and development
of new therapies is consistent with statements from the
Eurordis position paper on research priorities for RDs
2014–2020, a recent joint declaration by the European
Organisation for Rare Diseases (EURORDIS), the National
Organization for Rare Disorders (NORD) and the Canadian
Organization for Rare Disorders (CORD) 10 key principles
for RD patient REG, and the WA Rare Diseases Strategic
Framework 2015–2018 [5, 37, 39]. In addition to these find-
ings, we found several factors which, when utilised, served
to strengthen the success of RD resources. Collaboration,
engagement, blended recruitment, pro-active marketing,
broad consent, and “virtual BB” online catalogues were all
unique facilitators which enhanced the success of REG,
REG+BB, and RDBBs [14, 19, 34].
Despite their similarities in contributing to Omics re-
search, differences do exist between REG + BB and
RDBBs. The number of samples stored in REG + BB
compared to RDBBs was found to be entirely a function
of the resources, aims and objectives. REG + BB most
often stored small sample numbers, with most resources
storing only several hundred samples (such as The
German Calciphylaxis registry, which reported storing
253 samples). This was not always the case, however,
with the Eyegene registry collecting 4400 rare genetic
eye disorder samples. When compared to REG + BB, the
number of samples stored in RDBBs were typically much
larger, with samples stored being in the thousands. For
example, the Telethon Network of Genetic Biobanks re-
ported storing 75,900 samples from patients with RDs.
There were, however, small RDBBs that had collected
only 50 samples (such as the Friedrich’s Ataxia fibroblast
repository). Li et al. reported that smaller RDBBs have
their advantages over larger RDBB networks in the sense
that they can focus on a single diseases or syndromes, or
group of diseases, and can successfully accumulate sig-
nificant numbers of cell lines, whilst developing an in-
timate understanding of the disease [13].
REG + BB and RDBBs both have the capacity to collect,
store and conduct basic science investigations. It was
found RDBBs reported high quality control measures for
their samples. For example, in addition to standard sample
collection, the Japanese RDBB performs human leukocyte
antigen (HLA) analysis and mycoplasma (MC) testing to
their acquired samples. The HLA complex plays a key role
in the immune system response. Therefore, the Japanese
RDBB provided scientists not only with biological sam-
ples, but also with highly specialised HLA background
data with every specimen. Further, MC are known to in-
fect cell samples, which can lead to part of the cells me-
tabolism being affected. This RDBB reported an MC
contamination rate of 22.4% in their 1500 cell samples,
and subsequently introduced the MC test to ensure
high-quality sample management [52].
Key differences between REG, REG + BB, and RDBBs,
were observed in with regards to the number of diseases
each resource focused on. Both REG and REG + BB were
disease-specific resources, and as such focused their re-
search efforts on either a single disease in a specific
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population (such as the Swiss registry for pulmonary ar-
terial hypertension in a paediatric population) [20], or a
group of diseases (such as The UK JDM cohort bio-
marker study and repository Juvenile Dermatomyositis
(UK and Ireland) Cohort Biomarker study and Reposi-
tory for Idiopathic Inflammatory Myopathies) [29]. This
was not usually the case for RDBBs in this review, which
usually focused on multi-disease sample collection. For
example, the RDBB of Japan collected samples from 102
different RDs [52], and the Telethon Network of Genetic
BB collected samples from over 750 different RDs [19].
Another significant finding from our analyses is the dif-
ference in data collection methodologies between REG,
REG + BB when compared to larger RDBBs. We found
both REG and REG + BB typically collected comprehen-
sive clinical and epidemiological data. For example, The
UK Facioscapulohumeral muscular dystrophy patient
registry collected not only all the items in the minimal
dataset as identified at the 171st ENMC (European
Neuromuscular Centre) workshop, capturing demograph-
ics, genetics, motor function, and age at onset of disease,
but also collected highly encouraged data such as eye,
hearing, respiratory status and family history [21]. Further,
through validated questionnaires, the registry collected
outcomes relating to pain, quality of life, and scapular fix-
ation. Similar to REG and REG + BB, comprehensive data
collection was also a feature of small RDBBs. Ugolini et al.
stated that small RDBBs with a low number of specimens
should be compensated by the high quality of linked clin-
ical and epidemiological data [35]. Limited resources can
be overcome by the biorepository through specialisation
[13, 35]. Larger RDBBs, however, most often collected
minimum data sets. For example, the Telethon Network
of Genetic Biobanks collected patient particulars (name,
date of birth, etc.), phenotype (affected/not affected), an-
amnestic data (presence of consanguinity etc.), diagnosis
data (modality, centre performing diagnosis), and sample
data (code, type, data of collection, etc.) [19].
Both REG and REG + BB contributed to clinical obser-
vation and clinical treatment, but this was beyond the
scope of the RDBBs function in this review.
We demonstrated that there are key differences among
REG, REG + BB, and RDBBs. These differences are a
function of the resources’ design, aims, and objectives,
with each resource having a distinctive and important role
in contributing to the body of knowledge for RD research.
That said, this review underscores the unique scope and
utility of REG + BB, which has the function of both REG
(the capacity to collect comprehensive clinical and epi-
demiological data) and RDBB (the ability to contribute to
Omics research). Linkage of BBs to established RD regis-
tries offers a practical, cost-effective, and impactful solu-
tion for RD research. This is an important observation
that can serve to direct future RD research efforts.
Strengths and limitations
A limitation of this study is that our chosen search
terms used to locate all necessary and relevant RD regis-
tries and associated BBs may have led to a “filed-effect”
of articles, precluding other valuable studies from our
review by default. In addition, there is potential that
additional databases have been newly established due to
the study of RDs growing in momentum.
Conclusion
RDs are still under-researched worldwide. We examined
the research outcomes of three specific populations: REG,
REG + BB, and RDBBs. Whilst REG had the capacity to
uncover the natural history of disease, develop best prac-
tice, act as “real-world” studies supporting clinical trials,
and improve patient outcomes, they were limited in their
capacity to conduct basic research. The role of basic re-
search in RD research is vital; scientists must first under-
stand the pathways of disease before they can develop
appropriate interventions. RDBBs, on the other hand (par-
ticularly larger RDBBs), had the key infrastructure re-
quired to conduct basic research, making novel Omics
discoveries, identify and validate biomarkers, uncover
novel genes, and develop new therapeutic strategies. How-
ever, RDBB did not collect comprehensive data or impact
on clinical observations like REG. This review made the
important observation that REG + BB had the function of
both REG (the capacity to collect comprehensive clinical
and epidemiological data) and RDBB (the ability to con-
tribute to Omics research). We found REG + BB offers a
unique, practical, cost-effective, and impactful solution for
RD research. Linkage of REG to RDBBs will likely provide
the stronger foundation of resources required for the ef-
fective translation of basic research into clinical practice.
This is an important observation that can serve to direct
future RD research efforts. Furthermore, facilitators such
as collaboration, engagement, blended recruitment,
pro-active marketing, broad consent, and “virtual BB” on-
line catalogues will, if utilised, add to the success of REG,
REG + BB, and RDBBs [14, 19, 34].
Recommendations
The following evidence-based recommendations are de-
rived from this systematic review and align with the WA
Rare Disease Strategic Framework 2015–2018, and the
joint declaration of 10 key principles for RD patient
registries by the European Organisation for Rare
Diseases (EURORDIS), the National Organization for
Rare Disorders (NORD) and the Canadian Organization
for Rare Disorders (CORD).
1. Established stand-alone registries (REG) should be
identified, and, where appropriate, consider
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extending their research scope to include omics in-
vestigations as a research endpoin [20].
2. Established stand-alone registries (REG) choosing to
extend their research scope to include omics inves-
tigations should collaborate with stand-alone rare
disease Biobanks (RDBBs) for the collection, pro-
cessing, and storage of biological samples, that can
then be matched to clinical data in the registry [24].
3. The collaboration of REG with RDBBs should
enable a cross-over of each respective resources
functions (REG – comprehensive clinical data;
RDBB – omics investigations) to now have the
unique function of a REG + BB.
4. REG, REG + BB, and RDBBs resources should all
consider utilising the following facilitators to
enhance the success of the resource; engagement,
pro-active marketing, and achievement of informed
consent based on broad research goals.
5. REG + BB and RDBBs should consider establishing
an online “virtual BB” online catalogue to make
their resource known, and should create a steering
group consisting of representatives from the
following stakeholders; patients, patient support
groups, clinicians, and researchers to guide research
directions and activities [19].
6. REG, REG + BB, and RDBBs should adopt a
“blended recruitment” approach, ensuring the
largest possible geographical reach, with direct
(patient) or indirect (clinician) enrolment [34].
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